Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-05-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司产品列入WHO应急使用清单的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary's product being included in the WHO Emergency Use Listing (EUL). It details product approval information, market status, and impact on the company. The document is relatively short (2193 characters) and does not contain financial statements or detailed financial data. It is an announcement about a regulatory approval and product certification rather than a financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a certification letter or insider dealing report. The content is a regulatory announcement about product approval and market impact, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-05-10 Chinese
2020年面向合格投资者公开发行公司债券（第一期）在深圳证券交易所上市的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the listing of a corporate bond issued by Shenzhen BGI Genomics Co., Ltd. on the Shenzhen Stock Exchange. It details bond issuance terms such as bond names, codes, credit ratings, issuance amounts, interest rates, issuance and maturity dates, and trading information. The document does not contain financial statements or detailed financial performance data but rather provides information about the bond issuance and its listing on the exchange. This fits the category of Capital/Financing Update, which covers updates on company fundraising and financing activities.
2020-05-07 Chinese
关于持股5%以上股东减持股份计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's identity, shareholding percentage, planned reduction amount, methods, timing, and legal compliance. The content focuses on the shareholder's intention to reduce shares and related regulatory compliance, without financial statements or earnings data. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length is about 3107 characters, consistent with a detailed announcement but not a full financial report. Therefore, the appropriate classification is MRQ with high confidence.
2020-05-06 Chinese
关于控股子公司产品获得加拿大卫生部认证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding its subsidiary's product receiving certification from the Canadian Ministry of Health. It details the registration certificate, product information, market approvals in various countries, and the potential impact on the company. The document is relatively short (1861 characters) and serves as a regulatory announcement about a product certification rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about product certification and market approvals.
2020-05-06 Chinese
关于全资子公司产品获得新加坡HSA临时授权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary receiving a temporary authorization from the Singapore Health Sciences Authority (HSA) for a COVID-19 nucleic acid test kit. The text includes details about the product, the authorization, and its market impact. It references prior announcements about approvals in other markets but does not contain any financial data, management discussion, or detailed report content. The document is relatively short (1994 characters) and serves as a regulatory announcement about product authorization rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-05-06 Chinese
独立董事关于第二届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a board meeting matter about increasing the 2020 annual daily related-party transaction limit. It references compliance with stock exchange listing rules and company articles, and it is a formal opinion on a board resolution to be submitted to shareholders. The content focuses on board/management governance and internal decision-making rather than financial results, audit, or shareholder voting results. The document length is short (606 characters), and it is not an announcement of a report publication but a formal board-related opinion. Therefore, it fits best under Board/Management Information (MANG).
2020-04-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.